FMS - Greece Dialysis Center is a medicare approved dialysis facility center in Greece, New York and it has 17 dialysis stations. It is located in Monroe county at 1570 Long Pond Road, Greece, NY, 14626. You can reach out to the office of FMS - Greece Dialysis Center at (585) 225-1422. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FMS - Greece Dialysis Center has the following ownership type - Profit. It was first certified by medicare in June, 2015. The medicare id for this facility is 332725 and it accepts patients under medicare ESRD program.
| Name | FMS - Greece Dialysis Center |
|---|---|
| Location | 1570 Long Pond Road, Greece, New York |
| No. of Dialysis Stations | 17 |
| Medicare ID | 332725 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 1570 Long Pond Road, Greece, New York, 14626 | |
| (585) 225-1422 | |
News Archive
Within a decade, a combination of advanced measurement techniques and statistics will enable scientists to develop methods to diagnose serious diseases caused by genetic defects. Ten years after that, there may be medicines available to repair these defects.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.
Narcolepsy is a disorder of sleep regulation that affects control of wakefulness and sleep and renders the patient subject to disabling sleepiness during the day.
According to SEER data, more than 260,000 women were diagnosed with breast cancer in the United States in 2016, most of whom were diagnosed with early-stage (stage I or II) disease.
› Verified 3 days ago
| NPI Number | 1508260142 |
| Organization Name | Fms Greece Dialysis Center |
| Doing Business As | New York Dialysis Services, Inc. |
| Address | 1570 Long Pond Rd Greece, New York, 14626 |
| Phone Number | (585) 694-0308 |
News Archive
Within a decade, a combination of advanced measurement techniques and statistics will enable scientists to develop methods to diagnose serious diseases caused by genetic defects. Ten years after that, there may be medicines available to repair these defects.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.
Narcolepsy is a disorder of sleep regulation that affects control of wakefulness and sleep and renders the patient subject to disabling sleepiness during the day.
According to SEER data, more than 260,000 women were diagnosed with breast cancer in the United States in 2016, most of whom were diagnosed with early-stage (stage I or II) disease.
› Verified 3 days ago
| Dialysis patients with Hemoglobin data | 31 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 29 |
News Archive
Within a decade, a combination of advanced measurement techniques and statistics will enable scientists to develop methods to diagnose serious diseases caused by genetic defects. Ten years after that, there may be medicines available to repair these defects.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.
Narcolepsy is a disorder of sleep regulation that affects control of wakefulness and sleep and renders the patient subject to disabling sleepiness during the day.
According to SEER data, more than 260,000 women were diagnosed with breast cancer in the United States in 2016, most of whom were diagnosed with early-stage (stage I or II) disease.
› Verified 3 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 76 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 569 |
| Percentage of adult patients getting regular hemodialysis at the center | 95 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Within a decade, a combination of advanced measurement techniques and statistics will enable scientists to develop methods to diagnose serious diseases caused by genetic defects. Ten years after that, there may be medicines available to repair these defects.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.
Narcolepsy is a disorder of sleep regulation that affects control of wakefulness and sleep and renders the patient subject to disabling sleepiness during the day.
According to SEER data, more than 260,000 women were diagnosed with breast cancer in the United States in 2016, most of whom were diagnosed with early-stage (stage I or II) disease.
› Verified 3 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FMS - Greece Dialysis Center with elevated calcium levels.
| Patients with hypercalcemia | 79 |
| Hypercalcemia patient months | 578 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 82 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 28 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 31 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 23 |
| Patients with Serumphosphor greater than 7 mg/dL | 9 |
News Archive
Within a decade, a combination of advanced measurement techniques and statistics will enable scientists to develop methods to diagnose serious diseases caused by genetic defects. Ten years after that, there may be medicines available to repair these defects.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.
Narcolepsy is a disorder of sleep regulation that affects control of wakefulness and sleep and renders the patient subject to disabling sleepiness during the day.
According to SEER data, more than 260,000 women were diagnosed with breast cancer in the United States in 2016, most of whom were diagnosed with early-stage (stage I or II) disease.
› Verified 3 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 62 |
| Patient months included in arterial venous fistula and catheter summaries | 425 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 60 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 23 |
News Archive
Within a decade, a combination of advanced measurement techniques and statistics will enable scientists to develop methods to diagnose serious diseases caused by genetic defects. Ten years after that, there may be medicines available to repair these defects.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.
Narcolepsy is a disorder of sleep regulation that affects control of wakefulness and sleep and renders the patient subject to disabling sleepiness during the day.
According to SEER data, more than 260,000 women were diagnosed with breast cancer in the United States in 2016, most of whom were diagnosed with early-stage (stage I or II) disease.
› Verified 3 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 32 |
| Hospitalization Rate in facility | 255.7 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 497.6 |
| Hospitalization Rate: Lower Confidence Limit | 138.5 |
News Archive
Within a decade, a combination of advanced measurement techniques and statistics will enable scientists to develop methods to diagnose serious diseases caused by genetic defects. Ten years after that, there may be medicines available to repair these defects.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.
Narcolepsy is a disorder of sleep regulation that affects control of wakefulness and sleep and renders the patient subject to disabling sleepiness during the day.
According to SEER data, more than 260,000 women were diagnosed with breast cancer in the United States in 2016, most of whom were diagnosed with early-stage (stage I or II) disease.
› Verified 3 days ago
The rate of readmission show you whether patients who were being treated regularly at FMS - Greece Dialysis Center were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 22.7 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 40.4 |
| Readmission Rate: Lower Confidence Limit | 10.4 |
News Archive
Within a decade, a combination of advanced measurement techniques and statistics will enable scientists to develop methods to diagnose serious diseases caused by genetic defects. Ten years after that, there may be medicines available to repair these defects.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the results from its Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.
Narcolepsy is a disorder of sleep regulation that affects control of wakefulness and sleep and renders the patient subject to disabling sleepiness during the day.
According to SEER data, more than 260,000 women were diagnosed with breast cancer in the United States in 2016, most of whom were diagnosed with early-stage (stage I or II) disease.
› Verified 3 days ago